590.09
21.18 (3.72%)
| Previous Close | 568.91 |
| Open | 579.26 |
| Volume | 618,016 |
| Avg. Volume (3M) | 1,044,709 |
| Market Cap | 63,709,069,312 |
| Price / Earnings (TTM) | 15.01 |
| Price / Earnings (Forward) | 13.50 |
| Price / Sales | 4.61 |
| Price / Book | 2.09 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| TTM Dividend Yield | 0.15% |
| Profit Margin | 31.94% |
| Operating Margin (TTM) | 19.94% |
| Diluted EPS (TTM) | 39.31 |
| Quarterly Revenue Growth (YOY) | -3.70% |
| Quarterly Earnings Growth (YOY) | 12.00% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | 3.95 B |
| Levered Free Cash Flow (TTM) | 2.08 B |
| Return on Assets (TTM) | 6.91% |
| Return on Equity (TTM) | 15.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 1.13 |
|
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.58% |
| % Held by Institutions | 91.81% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,000.00 (JP Morgan, 69.47%) | Buy |
| Median | 834.00 (41.33%) | |
| Low | 547.00 (B of A Securities, -7.30%) | Sell |
| Average | 782.00 (32.52%) | |
| Total | 6 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 602.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 30 Apr 2025 | 587.00 (-0.52%) | Hold | 590.09 |
| 25 Apr 2025 | 652.00 (10.49%) | Hold | 602.64 | |
| UBS | 30 Apr 2025 | 633.00 (7.27%) | Hold | 590.09 |
| Truist Securities | 23 Apr 2025 | 975.00 (65.23%) | Buy | 587.85 |
| Canaccord Genuity | 22 Apr 2025 | 850.00 (44.05%) | Buy | 585.49 |
| Cantor Fitzgerald | 22 Apr 2025 | 695.00 (17.78%) | Buy | 585.49 |
| B of A Securities | 17 Apr 2025 | 547.00 (-7.30%) | Sell | 563.16 |
| Goldman Sachs | 14 Apr 2025 | 917.00 (55.40%) | Buy | 571.06 |
| JP Morgan | 31 Mar 2025 | 1,000.00 (69.47%) | Buy | 634.23 |
| Leerink Partners | 05 Feb 2025 | 834.00 (41.33%) | Buy | 716.72 |
No data within this time range.
| TTM Dividend Yield | 0.15% |
| Payout Ratio | 2.24% |
| Expected Next Dividend Payment | Mar 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.880 | 1 | 0.15 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |